title: Differential expression of the lung resistance-related protein/major vault protein in the histological compartments of nephroblastomas.
abstract: Nephroblastomas (Wilms' tumors) are curable with survival rates above 80%. Some tumors, however, fail to respond to therapy and those patients have a poor prognosis. In a search for molecular markers of drug resistance, we investigated the expression of lung resistance protein (LRP) in tissue samples from 32 children with nephroblastoma by means of immunohistochemistry. LRP is a human major vault protein (MVP) and is associated with multidrug resistance of tumors. LRP/MVP expression was found in the blastemal and epithelial compartments but to a significantly lesser extent in the stromal compartment of Wilms' tumors. Expression was generally heterogeneous with respect to staining intensity and percentage of positive cells. We found significant relationships between LRP/MVP expression and chemotherapeutic pre-treatment of tumors and tumor stage. The immunohistochemical results were validated with a real-time RT-PCR technique and a significant association between protein and mRNA expression was observed.
authors.affiliation: Virtual Campus Rhineland-Palatinate, D-55033 Mainz, Germany. efferth@vcrp.de
authors.forename: T
authors.initials: T
authors.lastname: Efferth
authors.forename: M E
authors.initials: ME
authors.lastname: Bode
authors.forename: H G
authors.initials: HG
authors.lastname: Schulten
authors.forename: P
authors.initials: P
authors.lastname: Thelen
authors.forename: B
authors.initials: B
authors.lastname: Granzen
authors.forename: A J
authors.initials: AJ
authors.lastname: Beniers
authors.forename: R
authors.initials: R
authors.lastname: Mertens
authors.forename: O
authors.initials: O
authors.lastname: Gefeller
authors.forename: R H
authors.initials: RH
authors.lastname: Ringert
authors.forename: G
authors.initials: G
authors.lastname: Jakse
authors.forename: L
authors.initials: L
authors.lastname: Fuzesi
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D017931:DNA Primers / Q000737:chemistry; D003609:Dactinomycin / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D006801:Humans; D007124:Immunoenzyme Techniques; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020394:Vault Ribonucleoprotein Particles / Q000235:genetics / Q000378:metabolism*; D014750:Vincristine / Q000627:therapeutic use; D009396:Wilms Tumor / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D001613:beta 2-Microglobulin / Q000378:metabolism; D000099187:Major Vault Protein
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D017931:DNA Primers; D003609:Dactinomycin; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D020394:Vault Ribonucleoprotein Particles; D014750:Vincristine; D001613:beta 2-Microglobulin; D000099187:Major Vault Protein